Bolstering a widely held view that Germany's Neuer Markt is perhaps the only hospitable Euro market for biotechs, Rhein Biotech (NMarkt:RBO) raised '24 million ($25.7 million) in its IPO on the Frankfurt exchange for growth stocks (see B16). The contract biogenerics technology developer opened at '30, the top of its range, and and gained '2.4 in its first day of trading Wednesday before closing the week at '29.8. It has a market cap of '89.4 million ($95.7 million).